 | |
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | carbohydrate antigen 125 |
| Clinical data | |
| Other names | DMUC5754A |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | 144.7 kg/mol |
Sofituzumab vedotin (INN; development code DMUC5754A) is a monoclonal antibody designed for the treatment of ovarian cancer.
This drug was developed by Genentech/Roche.
Sofituzumab vedotin is an antibody-drug conjugate that targets MUC16, a protein that is overexpressed in several types of cancer including ovarian and pancreatic cancer. The conjugate consists of a human anti-nectin-4 antibody linked to the cytotoxic agent MMAE, which is released after internalization by the cancer cell. In addition to its direct cytotoxic effect, sofituzumab vedotin may also mediate antitumor activity through signal transduction inhibition, antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity. Clinical trials have shown promising results in the treatment of ovarian and pancreatic cancer.
References
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Ralpancizumab, American Medical Association.
- "Sofituzumab Vedotin Overview - Creative Biolabs". www.creativebiolabs.net. Retrieved 2023-03-04.
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |